< Back to latest news & events

News

SkyKick ruling

January 2020

Specification of trade marks must be consistent with the essential function of indicating origin of the goods and services or risk being partially invalid for bad faith.

Case C-371/18 – Sky plc & ors v SkyKick UK Ltd & anor, 29 January 2019

Two days before the UK’s departure from the EU, the CJEU handed down its eagerly anticipated Judgment in SkyKick finding that a trade mark application made without any intention to use the trade mark in relation to the goods and services in the specification does constitute bad faith.  This was the case if the applicant had the intention either of undermining, in a manner inconsistent with honest practices, the interests of third parties, or of obtaining, without even targeting a specific third party, an exclusive right for purposes other than those falling within the functions of a trade mark.  However, this aspect of bad faith does not invalidate the entire trade mark (i.e., the “poisoned well”) but only the goods and services shown to have been applied for in bad faith.  The CJEU also indicated that it was permissible for national law to contain procedural requirements for an applicant to make a statement that he or she has bona fide intention to use a trade mark.  Such statements might be utilised as evidence in claims of bad faith but did not constitute a separate ground of invalidity.

The CJEU also held that a lack of clarity and precision of terms used to designate the goods or services (e.g., “computer software”) was not grounds for invalidity.  Furthermore, a trade mark cannot be declared wholly or partially invalid on the ground that terms used to designate the goods and services in respect of which that trade mark was registered lack clarity and precision.

Background

The case was referred by the UK High Court in an action where Sky plc (the broadcaster) claimed that SkyKick (at the time, a start-up company that supplied cloud migration information technology services) had infringed four EU trade marks and one UK trade mark consisting of the word SKY through use of the sign ‘SkyKick’ and variants thereof.  SkyKick denied infringement and counterclaimed for a declaration that the trade marks were invalidly registered, in whole or in part, on the grounds that: (i) the specifications of goods and services lacked clarity and precision and (ii) the applications were made in bad faith.  The claim in bad faith was based on the allegation that while Sky plc did intend to use for some of the goods and services in the specification, that had not intended to use the trade marks in relation to all of the goods and services specified.   SkyKick’s primary case was that the trade marks were invalid in their entirety (the “poisoned well” argument).  In the alternative, that the trade marks were partially invalid where Sky plc had not had any intention to use the trade marks.

Arnold J (as he was then) noted that SkyKick did not appear to have a defence to Sky plc’s claims for trade mark infringement despite the fact that the marks had not been used, and were not likely to be used, for many of the goods and services in respect of which they were registered.

Conclusions

This Judgment has far-reaching implications for, in particular, companies with trade mark portfolios containing multiple, broad trade mark filings in the EU.  The practice of filing extensively across multiple classes of goods and services and then “evergreening” such filings to avoid scrutiny for non-use are now likely to be critically examined by intellectual property offices and national courts.  Very few companies are likely to have a commercial justification for applying for trade marks with broad specifications across multiple classes.  Many will have already considered their portfolios following the AG’s opinion in October 2019 and will breathe a sigh of relief that the CJEU has confirmed that this type of bad faith will only partially invalidate the trade mark.  However, trade mark owners would be wise to consider the impact of the Judgment on their existing portfolios and filing practices.

This update was prepared by HGF Partner Rachel Fetches.  If you would like further advice on this or any other matter, please contact Rachel.  Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Latest updates

Event - 11th November 2025

OIS Investor Forum - Jeffries

HGF is proud to be sponsoring the OIS Investor Forum on 18th November. One of the premier gatherings for leaders, innovators, and investors across the healthcare industry. The forum covers …

Event details

From Stripes to Supermarkets: The Court of Appeal Reaffirms the Need for Precision in Trade Mark Law

On 23 October 2025, Lord Justice Arnold delivered two landmark Court of Appeal decisions addressing trade mark registrability: Thom Browne Inc & Anor v adidas AG [2025] EWCA Civ 1340 …

Read article

Protecting Digital Health innovation in the AI revolution

As artificial intelligence (AI) continues to transform healthcare, from diagnostic imaging and drug discovery to wearable devices and clinical decision support, questions around how to protect these advancements have become …

Read article

Doubling Up on Added Matter at the UPC

Following the UPC Court of Appeal (CoA) decision in Abbott v Sibio (APL_39664/2024, 14 February 2025) we now have a second CoA decision on added matter in expert Klein v …

Read article
Event - 4th November 2025

HGF are Silver Sponsors of LSPN Europe 2025

HGF is proud to be a Silver Sponsor of LSPN Europe 2025, a leading forum dedicated to helping life sciences innovators protect and leverage their intellectual property across the entire …

Event details
Event - 30th - 31st October 2025

RAPS European Digital Technologies and Software conference

HGF is proud to be attending the RAPS European Digital Technologies and Software conference in The Netherlands on 30th-31st October. HGF Partner and Patent Attorney Janine Swarbrick and Patent Director …

Event details

Protect It Before You Promote It: IP Advice for MedTech Innovators

Developed a new medical product? Check. Got tickets to an exciting MedTech conference to show off your new product? Check. Intellectual property? Pardon? In the excitement of bringing a new …

Read article

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it? This case centres on the evidence required to …

Read article